spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Bacterial Pneumonia 

 HSMN NewsFeed - 2 Dec 2019
Cumberland Pharmaceuticals Receives FDA Approval for RediTrex(TM) Product Line
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Nov 2019
Allergan Receives FDA Qualified Infectious Disease Product (QIDP) Designation And Fast Track Designation For ATM-AVI (Aztreonam And Avibactam) For Antibiotic-Resistant Gram-Negative Infections
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Mar 2019
Allergan Announces FDA Approval of AVYCAZ(R) (ceftazidime and avibactam) for Pediatric Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Nov 2018
Cumberland Pharmaceuticals To Acquire VIBATIV(R)
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 23 Apr 2018
Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV(R) (telavancin) at 2018 ECCMID(TM) Conference
Biopharmaceuticals
 HSMN NewsFeed - 2 Feb 2018
Appointment of Jonathan E. Gold as Interim Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Feb 2018
FDA Approves AVYCAZ(R) (ceftazidime and avibactam) for the Treatment of Patients with Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Sep 2017
Cardiome Announces Agreement with Basilea for Distribution of Zevtera(R)/Mabelio(R) (Ceftobiprole) in Europe and Israel
Biopharmaceuticals Licensing Distribution
 HSMN NewsFeed - 31 May 2016
Allergan Receives FDA Approval of TEFLARO(R) (ceftaroline fosamil) for Pediatric Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 May 2016
Theravance Biopharma Announces FDA Approval of Expanded Label for VIBATIV(R) (telavancin)
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Mar 2016
Zavante Therapeutics Closes $45 Million Series A Financing In Support Of U.S. Development For A First-In-Class Injectable Antibiotic
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 3 Mar 2016
Kris Peterson to Join Paratek Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Feb 2016
FDA Accepts Supplemental New Drug Application (sNDA) for TEFLARO(R) (ceftaroline fosamil)
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Sep 2014
Nabriva Therapeutics Appoints Dr Colin Broom as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Jan 2014
Cempra, Inc. Names David Moore as Chief Commercial Officer to Manage Commercial Development and Launch of Solithromycin and Taksta(TM)
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Dec 2013
Cubist Announces FDA Acceptance of Tedizolid New Drug Application with Priority Review
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Feb 2013
FDA Grants QIDP and Fast Track Designations for Cubist’s Late-Stage Antibiotic Candidates
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 May 2012
Paratek Announces Appointments of Dennis Molnar as Chief Executive Officer and Director and of Dr. Evan Loh as Chief Medical Officer and Chairman of the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jan 2011
Cempra Pharmaceuticals Names Carl Foster Executive Vice President of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Oct 2010
Forest Announces FDA Approval of Teflaro(TM) (ceftaroline fosamil) for the Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Sep 2010
FDA Advisory Committee Recommends Approval of Forest Laboratories' Ceftaroline Fosamil for the Treatment of Community Acquired Bacterial Pneumonia and Complicated Skin and Skin Structure Infections
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Aug 2010
Advanced Life Sciences Achieves Special Protocol Assessment Agreement With FDA for Restanza in Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Jun 2010
Tetraphase Closes $45 Million Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 6 May 2010
Cempra Pharmaceuticals Names Mark W. Hahn as Executive Vice President and Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Apr 2010
Cempra Announces Expansion of Clinical Management Team to Advance Leading Antibacterial Clinical Programs TAKSTA(TM) and CEM-101
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Dec 2009
Forest Laboratories Announces Acquisition of Additional Rights Related to NXL 104, a Novel Broad-Spectrum Beta-Lactamase Inhibitor
Biopharmaceuticals Licensing
 HSMN NewsFeed - 8 Oct 2009
Paratek Pharmaceuticals Signs Worldwide License and Commercialization Agreement for PTK 0796, Broad-Spectrum Oral and IV Antibiotic in Phase 3
Biopharmaceuticals Licensing
 HSMN NewsFeed - 12 Aug 2009
Forest Laboratories and AstraZeneca to Co-Develop and Commercialize a Late Stage Next Generation Anti-Infective
Biopharmaceuticals
 HSMN NewsFeed - 14 May 2009
Cempra Pharmaceuticals Closes $46 Million Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 24 Mar 2009
FDA Approves New Indication for Wyeth's TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Oct 2007
Roche and Trimeris Provide Update on Development of Alternative Administration Options for Delivery of FUZEON(R)
Biopharmaceuticals HIV/AIDS Drug Delivery
 HSMN NewsFeed - 11 Jun 2007
Response Biomedical Files for US FDA 510(k) Market Clearance of Rapid Influenza A+B Test
Diagnostics FDA
 HSMN NewsFeed - 1 Mar 2007
Results with New Integrase Inhibitor Plus FUZEON and Boosted Protease Inhibitor Show Remarkable Undetectable Rate of 98 Percent in Treatment-Experienced HIV Patients
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 1 Mar 2007
European Committee Issued Positive Opinions to Extend Indication for PREVENAR to Include Pneumonia and Otitis Media
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Oct 2006
Roche and Trimeris Provide Update on Development of Needle-Free Administration for FUZEON(R)
Biopharmaceuticals Drug Delivery HIV/AIDS
 HSMN NewsFeed - 5 Oct 2006
New Data Show Unprecedented Undetectable Rates of over 90 Percent in HIV Patients Receiving FUZEON(R) and Investigational Integrase Inhibitor MK-0518
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 26 Jun 2006
New Data Show FUZEON(R) Continues to Provide Significant Immune System Benefits in Patients Despite Ongoing Viral Replication
Biopharmaceuticals HIV/AIDS
Return to NewsFeed  

 Additional items found! 24

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 24 additional stories matching:
Bacterial Pneumonia
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.